Salgram Jaisinghani, MD
Nephrology · Louisville, KYNPI 1265544878
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $448, 2.1 times the $213 reported in 2021. That places this record below the midpoint for nephrology clinicians in KY, where the typical reported total is $1,122.
Across 45 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$154
- Takeda Pharmaceuticals U.S.A., Inc.$109
- AstraZeneca$98
- Novo Nordisk$58
- Calliditas Therapeutics US Inc.$50
- Johnson & Johnson$44
- plus $382 from 15 others
What the payments were for
- Food & beverage$895100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $109 |
| AstraZeneca | 5 | $98 |
| Novo Nordisk | 4 | $58 |
| Calliditas Therapeutics US Inc. | 3 | $50 |
| Johnson & Johnson | 2 | $44 |
| Scpharmaceuticals Inc. | 1 | $43 |
| Travere Therapeutics, Inc. | 2 | $40 |
| GSK | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Amgen | 2 | $33 |
| Bayer | 2 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $27 |
| Pfizer | 2 | $27 |
| Ardelyx, Inc. | 1 | $20 |
| Fresenius USA Marketing, Inc. | 1 | $15 |
| Novartis | 1 | $13 |
| AbbVie | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$895 in reported general payments places this provider in the 45th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Louisville
- Danny WooLouisville$427K
- Dawn CasterLouisville$193K
- Nizar AttallahLouisville$113K
- Shafic Abdul Wahab El HindiLouisville$45K
- George AronoffLouisville$26K
- Jai BhimaniLouisville$10K
- Alexander AfanasyevLouisville$10K
- William DuffLouisville$9K
- Bhagwan BhimaniLouisville$7K
- Aziz ChamiLouisville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.